Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720534 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Phase 2 study, sponsored by Arrowhead Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
NCT04720534 is a Phase 2 study that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 229 participants.
The verdict
NCT04720534, a Phase 2 study, has completed, sponsored by Arrowhead Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
Study Summary
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
Interventions
- DRUG Placebo
- DRUG ARO-APOC3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2021-05-31 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04720534
The ClinicalTrials.gov registry entry for NCT04720534 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04720534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04720534 about?
NCT04720534 is a clinical study titled "Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia". The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
What is the current status of trial NCT04720534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2021-05-31. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04720534?
The interventions under investigation include: Placebo (DRUG), ARO-APOC3 (DRUG).
Who is sponsoring clinical trial NCT04720534?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.